877-202-0205     support@chemchart.com     @chemchart
        
Sign In    Register
   Reset Filters

Experimental cancer drugs

Categories

Antineoplastic and immunomodulating drugs (45)
Antineoplastic drugs (45)
Pharmaceuticals (20)
Cyclic compounds (15)
Antineoplastic and immunomodulating drug (14)
Six-membered rings (6)
Five-membered rings (5)
Halides (4)
Organohalides (4)
Polycyclic organic compounds (4)
Thiazoles (4)
Acids (3)
DNA replication inhibitors (3)
Heterocyclic compounds (3)
Heterocyclic compounds (4 or more rings) (3)
Organic acids (3)
Organic peroxides (3)
Three-membered rings (3)
Trioxanes (3)
Alkylating antineoplastic agents (2)
Aromatic compounds (2)
Blister agents (2)
Carboxylic acids (2)
Chalcogenides (2)
Cycloalkanes (2)
Cyclopropanes (2)
Ethers (2)
Hydroxamic acids (2)
Nitrogen mustards (2)
Organochlorides (2)
Phosphorodiamidates (2)
Spiro compounds (2)
Tyrosine kinase inhibitors (2)
Alcohols (1)
Alkaloids (1)
Alkenes (1)
Amine oxides (1)
Angiogenesis inhibitors (1)
Aromatic compound (1)
Chloroarenes (1)
Cycloalkenes (1)
Cyclohexenes (1)
Enediynes (1)
Epoxides (1)
Fluoroarenes (1)
Ketones (1)
Macrocycles (1)
Morpholines (1)
Organobromides (1)
Organofluorides (1)
Oxazaphosphinans (1)
Oxides (1)
Piperazines (1)
Pyrrolidines (1)
Sulfides (1)
Sulfonic acids (1)
Terpenes and terpenoids (1)
Tetracyclic compounds (1)
Thioethers (1)
Topoisomerase inhibitors (1)

Suppliers

Sigma Aldrich (7)
Matrix Scientific (6)
AK Scientific (4)
Oakwood Chemical (2)
TCI Chemicals (1)

DICHLOROACETIC ACID (79-43-6)  
Bichloroacetic Acid  ·  Sodium Dichloroacetate  ·  Potassium Dichloroacetate
Dichloroacetic acid (DCA), sometimes called bichloroacetic acid (BCA), is the chemical compound with formula CHCl 2COOH. It is an acid, an analogue of acetic acid, in which 2 of the 3 hydrogen atoms of the methyl group have been replaced by chlorine atoms. Like the other chloroacetic acids, it has various practical applications.
Marimastat (154039-60-8)  
Marimastat was a proposed antineoplastic drug developed by British Biotech. It acted as a broad-spectrum matrix metalloproteinase inhibitor. Marimastat performed poorly in clinical trials, and development was terminated.
Glufosfamide (132682-98-5)  
Glufosfamide, also known as glucophosphamide, D-glucose isophosphoramide mustard, D-19575 is an experimental cytotoxic chemotherapeutic agent for treatment of malignancies.
Bestatin (65391-42-6, 58970-76-6)  
bestatin, (D-Leu)-(R-(R*,R*))-isomer  ·  bestatin, (L-Leu)-(S-(R*,S*))-isomer, hydrochloride  ·  bestatin, (L-Leu)-(R-(R*,R*))-isomer
Ubenimex (INN), also known more commonly as bestatin, is a competitive, reversible protease inhibitor. It is an inhibitor of arginyl aminopeptidase (aminopeptidase B), leukotriene A4 hydrolase (a zinc metalloprotease that displays both epoxide hydrolase and aminopeptidase activities), alanyl aminopeptidase (aminopeptidase M/N), leucyl/cystinyl aminopeptidase (oxytocinase/vasopressinase), and membrane dipeptidase (leukotriene D4 hydrolase). It is being studied for use in the treatment of acute myelocytic leukemia and lymphedema.
Vatalanib (212141-54-3)  
Vatalanib (INN, codenamed PTK787 or PTK/ZK) is a small molecule protein kinase inhibitor that inhibits angiogenesis. It is being studied as a possible treatment for several types of cancer, particularly cancer that is at an advanced stage or has not responded to chemotherapy. Vatalanib is orally active, that is, it is effective when taken by mouth.
Amonafide (69408-81-7)  
Amonafide (originally AS1413) (INN, trade names Quinamed and Xanafide) is a drug that is being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator. It is being developed as an anti-cancer therapy by Antisoma.
Bestatin (TN) (58970-76-6)  
Ubenimex (INN), also known more commonly as bestatin, is a competitive, reversible protease inhibitor. It is an inhibitor of arginyl aminopeptidase (aminopeptidase B), leukotriene A4 hydrolase (a zinc metalloprotease that displays both epoxide hydrolase and aminopeptidase activities), alanyl aminopeptidase (aminopeptidase M/N), leucyl/cystinyl aminopeptidase (oxytocinase/vasopressinase), and membrane dipeptidase (leukotriene D4 hydrolase). It is being studied for use in the treatment of acute myelocytic leukemia and lymphedema.
TIRAPAZAMINE (27314-97-2)  
Tirapazamine (SR-4233) is an experimental anticancer drug that is activated to a toxic radical only at very low levels of oxygen (hypoxia). Such levels are common in human solid tumors, a phenomenon known as tumor hypoxia. Thus, tirapazamine is activated to its toxic form preferentially in the hypoxic areas of solid tumors.
swainsonine (72741-87-8)  
Swainsonine is an indolizidine alkaloid. It is a potent inhibitor of Golgi alpha-mannosidase II, an immunomodulator, and a potential chemotherapy drug. As a toxin in locoweed (likely its primary toxin) it also is a significant cause of economic losses in livestock industries, particularly in North America.
sulforaphane (4478-93-7)  
Sulforaphane (sulphoraphane in British English) is a compound within the isothiocyanate group of organosulfur compounds. It is obtained from cruciferous vegetables such as broccoli, Brussels sprouts, and cabbages. It is produced when the enzyme myrosinase transforms glucoraphanin, a glucosinolate, into sulforaphane upon damage to the plant (such as from chewing), which allows the two compounds to mix and react.
TIAZOFURIN (60084-10-8)  
Tiazofurin is an inhibitor of IMP dehydrogenase. Tiazofurin and its analogues are under investigation for potential use in the treatment of cancer.
DMXAA (117570-53-3)  
Vadimezan (also known as or ASA404 and DMXAA) is a tumor-vascular disrupting agent (tumor-VDA) that attacks the blood supply of a cancerous tumor to cause tumor regression.
Irofulven (158440-71-2)  
Irofulven or 6-hydroxymethylacylfulvene (also known as HMAF of MGI-114) is an experimental antitumor agent. It belongs to the family of drugs called alkylating agents. It inhibits the replication of DNA in cell culture.
artemisinin (63968-64-9)  
qinghaosu  ·  quinghaosu  ·  artemisinine
Artemisinin, also known as qinghao su (Chinese: 青蒿素), and its semi-synthetic derivatives are a group of drugs used against Plasmodium falciparum malaria. It was discovered by Tu Youyou, a Chinese scientist, who was awarded half of the 2015 Nobel Prize in Medicine for her discovery. Treatments containing an artemisinin derivative (artemisinin-combination therapies, ACTs) are now standard treatment worldwide for P.
8-AZAGUANINE (134-58-7)  
Azaguanine  ·  Guanazolo  ·  8 Azaguanine
8-Azaguanine is a purine analog with the chemical formula C4H4N6O. It has been widely studied for its biological activity. It shows antineoplastic activity and has been used in the treatment of acute leukemia.
Troxacitabine (145918-75-8)  
Troxacitabine (brand name Troxatyl) is a nucleoside analogue with anticancer activity. Its use is being studied in patients with refractory lymphoproliferative diseases.
Prinomastat (192329-42-3)  
Prinomastat (code name AG-3340) is a matrix metalloproteinase (MMP) inhibitor with specific selectivity for MMPs 2, 3, 9, 13, and 14. Investigations have been carried out to determine whether the inhibition of these MMPs is able to block tumour metastasis by preventing MMP degradation of the extracellular matrix proteins and angiogenesis. Prinomastat underwent a Phase III trial to investigate its effectiveness against non-small cell lung cancer (NSCLC), in combination with gemcitabine chemotherapy.
Bropirimine (56741-95-8)  
Bropirimine is an experimental drug with anti-cancer and antiviral properties. It is an orally effective immunomodulator and is being tried in bladder cancers.
Atrasentan (173937-91-2)  
Atrasentan is an experimental drug that is being studied for the treatment of various types of cancer, including non-small cell lung cancer. It is also being investigated as a therapy for diabetic kidney disease. Atrasentan failed a phase 3 trial for prostate cancer in patients unresponsive to hormone therapy.
Imexon (59643-91-3)  
4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one  ·  BM-06002  ·  BM 06002
Imexon (INN, trade name Amplimexon) is a substance that is being studied in the treatment of some types of cancer, including pancreatic, lung, breast, prostate, melanoma, and multiple myeloma. It is a cyanoaziridine derivative.
Next Page >